Form 4: Gilead Sciences Increases Stake in Xilio Therapeutics Through Stock and Warrant Purchase

Gilead Sciences, a major shareholder in Xilio Therapeutics, has increased its holdings through the purchase of common stock and prefunded warrants.

Summary

• Gilead Sciences, Inc., a reporting person, filed a Form 4 detailing changes in beneficial ownership of Xilio Therapeutics, Inc. securities.
• On April 2, 2024, Gilead purchased 485,250 shares of Xilio Therapeutics common stock at a price of $0.76 per share.
• Following this transaction, Gilead directly owns 7,345,473 shares of Xilio Therapeutics common stock.
• Additionally, Gilead acquired 3,882,450 prefunded warrants with an exercise price of $0.0001 each.
• These warrants are exercisable at any time after issuance but are limited to ensure Gilead and its affiliates do not exceed 19.99% ownership of Xilio's common stock.
• The price of the derivative security is $0.7599.
• Following the transaction, Gilead owns 3,882,450 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. Gilead's increased investment suggests confidence in Xilio, but the filing itself is a routine disclosure.

Positives

• Gilead's increased investment in Xilio Therapeutics could signal confidence in the company's future prospects.
• The acquisition of prefunded warrants provides Gilead with the potential to further increase its stake in Xilio Therapeutics.

Risks

• The restriction on warrant exercise to maintain ownership below 19.99% could limit Gilead's ability to fully capitalize on its investment if Xilio's stock price increases significantly.
• The value of Gilead's investment in Xilio Therapeutics is subject to the risks associated with the biotechnology industry and the performance of Xilio's pipeline.

Future Outlook

The document does not contain specific forward-looking statements regarding Xilio Therapeutics' future performance or Gilead's future investment plans beyond the reported transactions.

Industry Context

Gilead's investment in Xilio Therapeutics reflects ongoing interest and investment in the biotechnology sector, particularly in companies developing novel therapies. This type of investment is common among large pharmaceutical companies seeking to expand their pipelines and access innovative technologies.

Comparison to Industry Standards

• Gilead Sciences is a large cap pharmaceutical company with a market capitalization of over $100 billion.
• Xilio Therapeutics is a small cap biotechnology company.
• Investments of this type are common in the pharmaceutical industry, with larger companies investing in smaller companies to gain access to new technologies and products.
• Comparable companies to Xilio Therapeutics include other small cap biotechnology companies focused on developing novel therapies.

Stakeholder Impact

• Shareholders of Xilio Therapeutics may view Gilead's increased investment positively.
• The investment could provide Xilio Therapeutics with additional resources to advance its research and development programs.

Key Dates